Prescripciones de opioides en España entre 2019 y 2020qué especialidades médicas lo están prescribiendo y en qué indicaciones

  1. Esperanza Regueras Escudero 1
  2. José López Guzmán 1
  1. 1 Universidad de Navarra
    info

    Universidad de Navarra

    Pamplona, España

    ROR https://ror.org/02rxc7m23

Journal:
MPJ Multidisciplinary Pain Journal

ISSN: 2697-2263

Year of publication: 2021

Issue: 1

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: MPJ Multidisciplinary Pain Journal

Abstract

Background: The prescription of opioids in the last years has been under scrutiny. In order to prevent a potential epidemic situation in Spain it is necessary to study the prescription dynamics in this country. Our current analysis will be focused on quantify the level of prescription by specialty and by indication. Methods: We analyzed prescription data provided by IQVIA© for all molecules and products classified in ATC-N2A (Narcotic analgesics) and ATC-N2B (non-narcotic analgesic) between 2019 to 2020. Data has been provided by IQVIA INFORMATION, S.A., extracted the 23th October 2020 containing 21,724 registries. We extracted the number of prescriptions by molecule and number of prescriptions by diagnostic grouping them by therapeutical areas. We did cross-analysis of prescriptions by diagnostic and by molecule, as well as prescriptions by molecule and specialty. All the calculations and data analysis were performed using Microsoft excel IOS 2019. Results: 3.2 million prescriptions of opioids of N2A-ATC group were filled in Spain in last 12 months by June 2020. Most prescribed molecules were tapentadol (36 %), fentanyl (28 %) and oxycodone-naloxone (13 %). 81 % of fentanyl prescriptions corresponded to patch formulation. 73 % of prescriptions were made by primary care doctors. Internal medicine specialists were, relatively more relevant as prescribers of fentanyl while rheumatologists were relatively more important as prescribers of oxycodone-naloxone. The three most important indications were back-pain (15 % of prescriptions), cancer (11 %) and osteohrosis (10 %). By therapeutical area, 38 % of prescriptions were made for orthopedic indications, 26 % for rheumatologic diseases and 11 % for oncological conditions. Conclusion: The number of step III opioids prescriptions grew 9.6 % in MAT (mobile annual tax) by June 2020 versus same period of 2019. 73 % of those prescriptions were concentrated in three molecules: tapentadol, fentanyl patch and oxycodone-naloxone. Primary care is the most relevant prescriber with 73 % of prescriptions. Oncological indications represent only the 11% of total prescriptions with the remaining 89 % corresponding to no-oncological indications.

Bibliographic References

  • O’Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3-19. DOI: 10.1002/ejp.970.
  • Chou R, Gordon DB, De Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131-57. DOI: 10.1016/j.jpain.2015.12.008.
  • Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med. 2015;49(3):409-13. DOI: 10.1016/j.amepre.2015.02.020.
  • Ringwalt C, Gugelmann H, Garrettson M, Dasgupta N, Chung AE, Proescholdbell SK, et al. Differential prescribing of opioid analgesics according to physician specialty for Medicaid patients with chronic noncancer pain diagnoses. Pain Res Manag. 2014;19(4):179-85. DOI: 10.1155/2014/857952.
  • Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25(2):171-86. DOI: 10.1016/0304-3959(86)90091-6.
  • Declaration of Montreal. IASP-PAIN.ORG. 2010. Disponible en: https://www.iasp-pain.org/DeclarationofMontreal [citado 10 de octubre de 2020].
  • Morone NE, Weiner DK. Pain as the fifth vital sign: exposing the vital need for pain education. Clin Ther. 2013;35(11):1728-32. DOI: 10.1016/j.clinthera.2013.10.001.
  • Campbell JN. APS 1995 Presidential address. Pain Forum. 1996;5(1):85-8. DOI: 10.1016/S1082-3174(96)80076-6.
  • Tynan MA, Polansky JR, Titus K, Atayeva R, Glantz SA. Tobacco use in top-grossing movies - United States, 2010-2016. MMWR Morb Mortal Wkly Rep. 2017;66:681-6. DOI: 10.15585/mmwr.mm6626a1.
Data source: Dialnet